Royalty Pharma has named Lucas Glass as Head of Artificial Intelligence, effective April 2026. In this position, Glass will oversee the integration of intelligent automation, advanced analytics and AI-driven decision support across the company’s royalty evaluation and investment processes.

Glass brings more than a decade of AI and data solutions experience in the life sciences industry, most recently serving as Senior Vice President of Technology at IQVIA. His prior roles include data science leadership positions at Routine Recovery and the U.S. Department of Justice, underpinned by advanced degrees in statistics and biostatistics.

The addition of an AI-focused leader is expected to enhance Royalty Pharma’s competitive advantage by improving decision-making efficiency and driving more informed royalty investments. Management aims to leverage Glass’s expertise to accelerate technology deployment and support its large portfolio of over 35 commercial biopharmaceutical royalties.